

Complement Activation and Hemolysis in Non-Human Primates Following Transfusion of Genetically Modified Pig Red Blood Cells

Hee Jung Kang, M.D., Ph.D.¹, Juhye Roh, M.D., Ph.D.¹, Haneulnari Lee, M.S.¹, Eun Mi Park, M.S.¹, Hye Won Lee, M.S.¹, Ju Young Lee, Ph.D.², Jeong Ho Hwang, D.V.M., Ph.D.², Joohyun Shim, Ph.D.³, and Kimyung Choi, Ph.D.³

¹Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea; ²Animal Model Research Group, Jeonbuk Branch Institute, Korea Institute of Toxicology, Jeongeup, Korea; ³Department of Transgenic Animal Research, Optipharm Inc., Cheongju, Korea

Supplemental Data Table S1. Information on the reagents used in this study

Target	Product information (Company)	Purpose	Limit of detection	Range of calibrators	Recommended dilutions of samples	Precision (intra-/inter-assay)
Factor Bb	MicroVue Bb plus EIA (Quidel)	<i>In-vitro</i> diagnostic use	0.018 µg/mL	0–6.0 µg/mL	1:20	2.4%–2.5%/ 6.7%–7.7%
C3a	BD OptEIA Human C3a ELISA Kit (BD Biosciences)	Research use only	0.007 ng/mL	0–5.0 ng/mL	1:100–1:3200	6.8%–7.1%/ 7.1%–9.4%
C4a	BD OptEIA Human C4a ELISA Kit (BD Biosciences)	Research use only	0.006 ng/mL	0–2.0 ng/mL	1:500–1:4000	5.8%–6.5%/ 6.5%–9.7%